Neuromelanin MRI detects monoaminergic cell loss in Huntington Disease Expansion Gene Carriers.
Objective: To measure, with NM-MRI, the integrity of neuromelanin-containing monoaminergic cells in the SN and LC in Huntington Disease Gene Expansion Carriers (HDGECs) and compare…Grey-matter volume changes underpinning irritability and aggression in early manifest Huntington’s disease
Objective: To explore grey-matter volume (GMV) differences between early-stage Huntington's disease (HD) patients with and without significant irritability/aggression symptoms (IAs) and to assess it association…Quantitative Motor (Q-Motor) Assessments Suggest a Beneficial Central Effect of Laquinimod in a Phase II Study in Huntington Disease (LEGATO-HD)
Objective: Evaluate the change from baseline at week 52 in Q-Motor (Quantitative Motor) measures, exploratory, standardized, and rater-independent outcomes in the LEGATO-HD study. Background: LEGATO-HD…Long-term impact of Levodopa Carbidopa Intestinal Gel (LCIG) on reducing “Off” time: Results from a systematic review of studies with ≥ 12 months of follow-up
Objective: The objective of this study was to summarize evidence evaluating long-term (i.e. ≥ 12 months)efficacy of levodopa carbidopa intestinal gel (LCIG) on “off” time,…Effectiveness and safety of a herbal medication, HH368, for clinical symptoms of idiopathic Parkinson’s disease: a randomized controlled, pilot trial protocol
Objective: This study aims to assess feasibility of a herbal medication, HH368 for idiopathic Parkinson's disease (PD) patients who are in Hoehn & Yahr stage…Influence of disease severity in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II
Objective: To evaluate the impact of disease severity on the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s disease (PD) patients with motor fluctuations. Background: OPC,…Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline dopamine agonist use: post-hoc analysis from double-blind combined BIPARK-I and II data
Objective: To evaluate the incidence of treatment-emergent adverse events (TEAEs) in levodopa-treated Parkinson’s disease (PD) patients with motor fluctuations and taking opicapone (OPC). Background: OPC…A Phase 2 Dose Escalation Study of Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, Given Once-Daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects with Synucleinopathies
Objective: To assess the acute effects of ampreloxetine on the pressor response, improvement of symptoms and safety in a daily, single, escalating doses. Background: nOH…Population Pharmacokinetics and Pharmacodynamics of Ampreloxetine (TD-9855) in Patients with Neurogenic Orthostatic Hypotension (nOH)
Objective: To characterize the Phase 2 pharmacokinetics (PK) and pharmacodynamics (PD) of ampreloxetine in patients with nOH and provide dosing recommendations for special populations in…Rivastigmine for visual hallucinations in Parkinson’s disease
Objective: The aim of the study is to investigate whether early rivastigmine treatment of visual hallucinations in patients with Parkinson's disease delays the progression of…
- « Previous Page
- 1
- …
- 109
- 110
- 111
- 112
- 113
- …
- 217
- Next Page »